Comparative Pharmacology
Head-to-head clinical analysis: QUESTRAN versus WELCHOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUESTRAN versus WELCHOL.
QUESTRAN vs WELCHOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby preventing their enterohepatic reabsorption and increasing hepatic LDL receptor activity and cholesterol catabolism.
Welchol (colesevelam) is a bile acid sequestrant. It binds to bile acids in the intestine, forming an insoluble complex that is excreted in the feces. This disrupts the enterohepatic circulation of bile acids, leading to increased hepatic conversion of cholesterol to bile acids, resulting in decreased serum low-density lipoprotein cholesterol (LDL-C). Additionally, colesevelam may improve glycemic control in type 2 diabetes by binding to bile acids, which alters farnesoid X receptor (FXR) and TGR5 signaling, leading to increased glucagon-like peptide-1 (GLP-1) secretion and improved insulin sensitivity.
Questran (cholestyramine) is administered orally. The typical adult dose is 4 grams (one packet or one level scoop) once or twice daily, with a maximum of 24 grams per day. The powder should be mixed with at least 120 mL of fluid (e.g., water, juice).
Adults: 625 mg to 1.875 g orally twice daily, with meals. Maximum 4.375 g/day.
None Documented
None Documented
Not applicable; the drug is not absorbed and does not have a systemic half-life. Clinical effect persists as long as the resin remains in the gut (approximately 6-8 hours per dose).
Not applicable; colesevelam acts locally in the gastrointestinal tract and is not absorbed systemically. Terminal half-life is not measurable in conventional pharmacokinetic sense due to negligible systemic absorption.
Cholestyramine is not absorbed from the gastrointestinal tract; therefore, it is excreted entirely in the feces as the intact resin, with no renal or biliary excretion.
Primarily fecal as unchanged drug (approximately 85%), with less than 0.5% renal excretion of absorbed drug; no biliary excretion due to non-absorbed nature.
Category C
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant